China Traditional Chinese Medicine Holdings Co. Limited has announced that the National Medical Products Administration (NMPA) of China has accepted the new drug application for Yushuda Tablets, a Class 1.1 innovative traditional Chinese medicine developed by its subsidiary, Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd. The acceptance marks the start of a series of regulatory review procedures, including technical evaluation and on-site inspection. Yushuda Tablets have shown significant efficacy in treating symptoms associated with qi stagnation and mild-to-moderate depression. While this is a promising development, the timeline for final approval remains uncertain, and shareholders are advised to exercise caution.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。